0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bioengineered Protein Drugs - Global Strategic Business Report

  • PDF Icon

    Report

  • 193 Pages
  • February 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1382359
The global market for Bioengineered Protein Drugs was valued at US$257.6 Billion in 2024 and is projected to reach US$329.9 Billion by 2030, growing at a CAGR of 4.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Bioengineered Protein Drugs - Key Trends and Drivers

The growth in the bioengineered protein drugs market is driven by several factors, including technological advancements, increased prevalence of chronic diseases, and growing acceptance and demand for personalized medicine. Technological innovations have streamlined the drug development process, reducing costs and time-to-market, while biopharmaceutical companies are leveraging these advancements to develop more potent and targeted therapies. The rising incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders has also heightened the demand for these advanced treatments. Furthermore, consumer behavior trends indicate a strong preference for personalized medicine, which bioengineered proteins are uniquely positioned to deliver due to their ability to be tailored to individual genetic profiles. Additionally, favorable regulatory policies and increased healthcare funding in many regions are supporting the rapid market expansion. Investment in research and development by both private and public sectors is also pivotal, driving continuous innovation and the introduction of next-generation biopharmaceuticals.

The regulatory landscape for bioengineered protein drugs is stringent, reflecting the need for ensuring safety and efficacy given their biological origin and complexity. The approval process typically involves extensive clinical trials and post-marketing surveillance to monitor adverse effects and long-term outcomes. Innovations in biotechnology, such as CRISPR and other gene-editing tools, have further accelerated the development of these drugs, enabling more precise modifications and potentially reducing development times. Moreover, advancements in bioprocessing and manufacturing techniques have improved the scalability and cost-effectiveness of producing bioengineered proteins. As these technologies evolve, the pipeline of bioengineered protein drugs continues to expand, addressing unmet medical needs and offering new hope for patients with previously untreatable conditions.

Bioengineered protein drugs, also known as biopharmaceuticals, have revolutionized the field of medicine, offering targeted and effective treatments for a wide range of diseases. These drugs are developed using advanced genetic engineering techniques that allow for the production of proteins identical to those naturally occurring in the human body. These proteins can be designed to interact with specific biological pathways, enabling precise intervention in disease mechanisms. Examples include monoclonal antibodies, used in cancer therapy, and insulin analogs for diabetes management. The complexity of their development, involving recombinant DNA technology and rigorous purification processes, ensures high specificity and efficacy, distinguishing them from traditional small-molecule drugs. As a result, bioengineered protein drugs have become a cornerstone in treating chronic conditions such as rheumatoid arthritis, multiple sclerosis, and various types of cancers.

Report Scope

The report analyzes the Bioengineered Protein Drugs market, presented in terms of market value (USD). The analysis covers the key segments and geographic regions outlined below.

Segments

Type (Therapeutic Proteins, Monoclonal Antibodies, Vaccines); End-Use (Pharma & Biotech Companies, CROs, Academics).

Geographic Regions/Countries

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Therapeutic Proteins segment, which is expected to reach US$129.2 Billion by 2030 with a CAGR of a 3.8%. The Monoclonal Antibodies segment is also set to grow at 4.2% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $68.7 Billion in 2024, and China, forecasted to grow at an impressive 7.1% CAGR to reach $69.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Bioengineered Protein Drugs Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Bioengineered Protein Drugs Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Bioengineered Protein Drugs Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Abbott India Ltd., Amgen, Inc., Bayer AG, Biocon Ltd., Dr. Reddy's Laboratories Ltd. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 56 companies featured in this Bioengineered Protein Drugs market report include:

  • Abbott India Ltd.
  • Amgen, Inc.
  • Bayer AG
  • Biocon Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Panacea Biotec Ltd.
  • ProBioGen AG

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Bioengineered Protein Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Advances in Genetic Engineering Propel Growth in Bioengineered Protein Drugs Market
  • Increasing Prevalence of Chronic Diseases Expands Addressable Market Opportunity
  • Personalized Medicine Trends Strengthen Business Case for Bioengineered Proteins
  • Innovations in Bioprocessing Technologies Drive Cost-Efficiency and Scalability
  • Rising Consumer Demand for Targeted Therapies Generates Opportunities
  • Adoption of CRISPR and Gene-Editing Tools Accelerates Development Timelines
  • Healthcare Funding Increases Propel Market Adoption
  • Enhanced Purification Techniques Improve Drug Safety and Efficacy
  • Advanced Manufacturing Technologies Enhance Production Capabilities
  • Post-Marketing Surveillance Strengthens Confidence in Bioengineered Protein Drugs
  • Technological Synergies with Digital Health Tools Enhance Treatment Outcomes
  • Novel Drug Delivery Systems Expand Therapeutic Applications
  • Data Analytics and AI Integration Improve Drug Development Efficiency
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Bioengineered Protein Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 3: World Historic Review for Bioengineered Protein Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 4: World 15-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Therapeutic Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 6: World Historic Review for Therapeutic Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 7: World 15-Year Perspective for Therapeutic Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 9: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 10: World 15-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 12: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 13: World 15-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 15: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 16: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 18: World Historic Review for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 19: World 15-Year Perspective for CROs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Academics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 21: World Historic Review for Academics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 22: World 15-Year Perspective for Academics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • Table 23: USA Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 24: USA Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 25: USA 15-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2015, 2025 & 2030
  • Table 26: USA Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 27: USA Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 28: USA 15-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2015, 2025 & 2030
CANADA
  • Table 29: Canada Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 30: Canada Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 31: Canada 15-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2015, 2025 & 2030
  • Table 32: Canada Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 33: Canada Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 34: Canada 15-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2015, 2025 & 2030
JAPAN
  • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • Table 35: Japan Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 36: Japan Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 37: Japan 15-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2015, 2025 & 2030
  • Table 38: Japan Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 39: Japan Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 40: Japan 15-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2015, 2025 & 2030
CHINA
  • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • Table 41: China Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 42: China Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 43: China 15-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2015, 2025 & 2030
  • Table 44: China Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 45: China Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 46: China 15-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2015, 2025 & 2030
EUROPE
  • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • Table 47: Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 48: Europe Historic Review for Bioengineered Protein Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 49: Europe 15-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • Table 50: Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 51: Europe Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 52: Europe 15-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2015, 2025 & 2030
  • Table 53: Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 54: Europe Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 55: Europe 15-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2015, 2025 & 2030
FRANCE
  • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • Table 56: France Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 57: France Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 58: France 15-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2015, 2025 & 2030
  • Table 59: France Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 60: France Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 61: France 15-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2015, 2025 & 2030
GERMANY
  • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • Table 62: Germany Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 63: Germany Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 64: Germany 15-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2015, 2025 & 2030
  • Table 65: Germany Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 66: Germany Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 67: Germany 15-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2015, 2025 & 2030
ITALY
  • Table 68: Italy Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 69: Italy Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 70: Italy 15-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2015, 2025 & 2030
  • Table 71: Italy Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 72: Italy Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 73: Italy 15-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2015, 2025 & 2030
UNITED KINGDOM
  • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • Table 74: UK Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 75: UK Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 76: UK 15-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2015, 2025 & 2030
  • Table 77: UK Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 78: UK Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 79: UK 15-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2015, 2025 & 2030
SPAIN
  • Table 80: Spain Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 81: Spain Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 82: Spain 15-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2015, 2025 & 2030
  • Table 83: Spain Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 84: Spain Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 85: Spain 15-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2015, 2025 & 2030
RUSSIA
  • Table 86: Russia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 87: Russia Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 88: Russia 15-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2015, 2025 & 2030
  • Table 89: Russia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 90: Russia Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 91: Russia 15-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2015, 2025 & 2030
REST OF EUROPE
  • Table 92: Rest of Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 93: Rest of Europe Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 94: Rest of Europe 15-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2015, 2025 & 2030
  • Table 95: Rest of Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 96: Rest of Europe Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 97: Rest of Europe 15-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2015, 2025 & 2030
ASIA-PACIFIC
  • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 99: Asia-Pacific Historic Review for Bioengineered Protein Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 100: Asia-Pacific 15-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 102: Asia-Pacific Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 103: Asia-Pacific 15-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2015, 2025 & 2030
  • Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 105: Asia-Pacific Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 106: Asia-Pacific 15-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2015, 2025 & 2030
AUSTRALIA
  • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott India Ltd.
  • Amgen, Inc.
  • Bayer AG
  • Biocon Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Panacea Biotec Ltd.
  • ProBioGen AG

Table Information

This website uses cookies to ensure you get the best experience. Learn more